Clinical trial
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage…
NCT00003222 · University of Virginia, Other · Completed
Key facts
| NCT number | NCT00003222 |
|---|---|
| Title | Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | Phase II Trial for the Evaluation of the Efficacy of Vaccination With Synthetic Melanoma Peptides Either Pulsed on Dendritic Cells, or Administered With GM-CSF-in-Adjuvant, Plus Administration of Sustemic IL-2, in Patients With Advanced Melanoma. |
| Lead sponsor | University of Virginia, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tetanus peptide melanoma vaccine, tyrosinase peptide |
| Enrollment | 40 |
| Start date | Apr 1, 1998 |
| Primary completion | Sep 1, 2003 |
| First posted | Feb 9, 2004 |
| Last update posted | Dec 19, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: